MERCIA PATRICIA FERREIRA CONCEICAO
Projetos de Pesquisa
Unidades Organizacionais
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina
5 resultados
Resultados de Busca
Agora exibindo 1 - 5 de 5
- Prognostic and predictive value of Pleckstrin homology-like domain, family A family members in breast cancer(2020) MANGONE, Flavia R.; VALOYES, Maira A. V.; NASCIMENTO, Renan G. do; CONCEICAO, Mercia P. F.; BASTOS, Daniel R.; PAVANELLI, Ana C.; SOARES, Ibere C.; MELLO, Evandro S. de; NONOGAKI, Suely; OSORIO, Cynthia A. B.; NAGAI, Maria A.Aim: The PHLDA (pleckstrin homology like domain, family A) gene family encodes proteins capable of inhibiting AKT (serine/threonine kinase) signaling through phosphoinositol binding competition. Results & methodology: Using in silico analysis, we found that Luminal A and B patients' short relapse-free survival was associated with low PHLDA1 or PHLDA3 and high PHLDA2 expression. In a cohort of 393 patients with luminal breast cancer evaluated by immunohistochemistry on tissue microarrays, we found a direct association of PHLDA3 expression with hormonal therapy response (p = 0.013). Conclusion: Our findings provide new information on the role played by the PHLDA family members as prognostic markers in breast cancer, and more importantly, we provide evidence that they might also predict a response to endocrine therapy.
bookPart Morte celular(2022) CONCEIçãO, Mércia Patrícia Ferreira; SAITO, Renata de Freitas; BUSTOS, Silvina Odete- Oncology and Hematology in the ICU(2022) NASCIMENTO, R. G. Do; PAULA, N. A. B. Garrido de; CONCEIçãO, M. Ferreira; BASTOS, D. R. De; CERQUEIRA, D. De OliveiraIn the coming years, accelerated progress against oncologic and hematologic diseases will be associated with a greater number of patients requiring life support therapies. In this chapter, we seek to highlight recent changes in the use and outcomes of intensive care in onco-hematologic patients. In recent decades, we have shown a substantial increase in our understanding of organ dysfunctions in the population of patients with solid and hematological malignancies, in the more appropriate use of life support therapies and in the selection of new and better therapeutic approaches that have been increasing survival of these patients. While reading this chapter, the reader is expected to reflect on the daily management of critically ill onco-hematological patients, from the management of toxicity to palliative care, and to understand the role and importance of the pharmacist within the field of oncology among critically ill patients. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.
- Altered Expression of CYSLTR1 is Associated With Adverse Clinical Outcome in Triple Negative Breast Tumors: An In Silico Approach(2023) CESPEDES, Andres Galindo; CONCEICAO, Mercia Patricia Ferreira; BASTOS, Daniel Rodrigues de; GRAZIA, Gabriela avila de; LEITE, Jean Michel Rocha Sampaio; NASCIMENTO, Renan Gomes do; FERREIRA, Matthew Thomas; LOPEZ, Rossana MendozaObjective: Triple negative breast cancer (TNBC) has high relapse rates due to dysregulated inflammatory signaling pathways and significant changes in the tumor microenvironment, probably influencing the failure of several therapies. The Cysteinyl Leukotriene Receptor 1 (CYSLTR1), a leukotriene modulator of inflammation, has been shown to play an important role in cancer pathogenesis and survival but few studies have been reported on its role in breast cancer. Materials and Methods: The present work was conducted using publicly available platforms that have omics data to assess the clinical potential of CYSLTR1 expression and its prognostic validation in large cohorts of samples from breast cancer patients. Web platforms containing clinical information, RNA-seq and protein data were selected to perform in silico analyses of the potential marker CYLSTR1. Added together, the platforms included modules for correlation, expression, prognosis, drug interactions, and construction of gene networks.Results: Kaplan-Meier curves revealed that reduced levels of CYSLTR1 corresponded to an unfavorable outcome for overall survival (p<0.005) as well as relapse-free survival (p<0.001) in the basal subtype. Additionally, CYSLTR1 was downregulated in breast tumor samples compared to adjacent healthy tissue (p<0.01) and the basal subtype exhibited the lowest expression of CYSLTR1 relative to the other subtypes (p<0.0001). Furthermore, gene networking analysis showed strong associations of CYSLTR1 with two protein-coding genes (P2RY10 and XCR1) when tested on a TNBC dataset. Conclusion: Our data highlighted the relevance of CYSLTR1 since it may play an important role in TNBC therapy. However, further in vitro and in vivo studies should be directed towards validating our findings in an effort to improve our understanding of TNBC pathology.
- PHLDA3 (pleckstrin homology-like domain, family A, member 3)(2020) FERREIRA, M.P.; NAGAI, M.A.Review on PHLDA3, with data on DNA, on the protein encoded, and where the gene is implicated. © 2020 Atlas of Genetics and Cytogenetics in Oncology and Haematology.